Cannabis and Neuropathic Pain

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

Not Medical Advice

This article is not medical advice. It summarizes published research for educational purposes only. Neuropathic pain has many underlying causes and interacts with other conditions, medications, and psychiatric factors. If you have nerve pain, consult a clinician—ideally one with experience in both pain medicine and cannabinoid pharmacology. Do not stop or reduce prescribed medications based on this article.

Cannabis interacts with several medications, including warfarin (anticoagulant), clobazam (antiepileptic), and certain statins and immunosuppressants, through inhibition of liver enzymes. See Cannabis and Polypharmacy Risks for details. Cannabis is contraindicated in personal or strong family history of psychosis or bipolar disorder, and in pregnancy and breastfeeding.

Plain-Language Summary

Neuropathic pain is pain caused by damage to or disease of the nerves themselves, rather than injury to skin, muscle, or bone. It typically feels like shooting, burning, electric, or pins-and-needles sensations. Common causes include diabetes (diabetic neuropathy), viral infection (post-shingles pain), multiple sclerosis, HIV, chemotherapy, spinal cord injury, and traumatic nerve injury (sciatica, brachial plexus injury).

Standard first-line treatments—gabapentin, pregabalin, duloxetine, amitriptyline, and opioids—provide meaningful relief for many people. However, a significant portion either do not respond adequately or experience intolerable side effects, leaving a genuine treatment gap.

Cannabis has been studied in dozens of randomized controlled trials (RCTs) for neuropathic pain. The honest summary: it works modestly for some people in some conditions, with a side-effect profile most tolerating participants can manage, but about 1 in 4 to 1 in 3 discontinue due to adverse effects. Effect sizes are in the range of 20–30% pain reduction versus 15–20% for placebo Strong evidence^[1]. Most trials run 2–15 weeks; long-term benefit is unknown.

What Probably Works

Nabiximols (Sativex) for MS-related neuropathic pain and spasticity-associated pain. This is the strongest evidence base. Multiple RCTs and systematic reviews show modest but reproducible pain reduction compared to placebo Strong evidence^[2][3][4]. A 2007 trial in 337 MS patients found nabiximols produced clinically relevant benefit in roughly 40% of responders Strong evidence^[4]. Nabiximols is approved for this indication in the UK, Canada, and several other countries. Number needed to treat is approximately 5–6.

Smoked or vaporized cannabis for HIV-associated sensory neuropathy. Two well-designed RCTs (Abrams et al. 2007 and Ellis et al. 2009) from UCSF and UCSD showed pain reduction of approximately 30% in responders, with a number needed to treat around 3–5 Strong evidence^[5][6]. These remain among the most rigorous trials in the cannabis pain literature.

Mixed chronic neuropathic pain in adults (pooled evidence). A 2018 Cochrane systematic review of 18 RCTs and a 2017 National Academies of Sciences report both concluded there is substantial or conclusive evidence that cannabis or cannabinoids are effective for chronic pain in adults, with neuropathic pain among the best-represented subtypes Strong evidence^[1][2]. Typical effect sizes are modest—20–30% pain reduction versus 15–20% on placebo, yielding a number needed to treat of roughly 5–11 depending on condition and dose.

What Might Work (Limited Evidence)

Diabetic peripheral neuropathy. A 2015 RCT by Wallace et al. showed dose-dependent pain reduction with inhaled cannabis, but the trial was small (n=16, crossover design) and short (5 weeks) Weak / limited^[7]. Reasonable to consider when standard agents (gabapentin, pregabalin, duloxetine) fail or are not tolerated, but evidence is thin.

Spinal cord injury neuropathic pain. Two small exploratory trials with oral THC and nabiximols reported benefit, but sample sizes were limited (n=24–25) and designs were open-label or short-term crossover Weak / limited^[8]. Not yet adequate for confident recommendation.

CBD alone for neuropathic pain. Cannabidiol (CBD) is biologically plausible—it may modulate inflammatory and pain signaling pathways—and is heavily marketed for neuropathy. However, high-quality RCTs of isolated CBD for neuropathic pain in humans are sparse and largely negative or underpowered Weak / limited. Most positive trials in neuropathic pain use THC-containing products. Topical CBD is also marketed but evidence is minimal (see below). See the CBD article for more detail on the gap between preclinical signal and clinical evidence.

What Doesn't Work or Has Weak Evidence

Chemotherapy-induced peripheral neuropathy (CIPN). Despite strong clinical interest and significant unmet need, controlled trials of cannabinoids for CIPN have been disappointing. A 2014 crossover trial of oral cannabinoid extract showed no significant pain reduction versus placebo Weak / limited^[9]. This is counterintuitive and remains unexplained—CIPN may respond differently to cannabinoids than other neuropathic conditions, or the doses and durations studied may have been suboptimal.

Topical CBD or cannabis creams for nerve pain. Heavily marketed but minimally studied. One 2020 trial reported symptom improvement with topical CBD for peripheral neuropathy symptoms, but the trial was small (n=52) and lacked adequate blinding Weak / limited^[10]. Transdermal absorption of cannabinoids is generally poor, and evidence does not yet support topical cannabis products for neuropathic pain.

Strain type predicting pain relief ("Indica vs Sativa"). Popular belief holds that "indica" strains are better for pain than "sativa" strains. This is folklore, not pharmacology. The botanical distinction between indica and sativa does not reliably predict chemical composition (THC:CBD ratio, terpene profile) or clinical effects No data. See Indica vs Sativa for more.

Specific terpene profiles for neuropathic pain. Beta-caryophyllene and myrcene are promoted as pain-relieving terpenes. Beta-caryophyllene is a CB2 agonist in preclinical studies, and myrcene shows analgesic activity in animal models. However, no robust human RCTs support their use for neuropathic pain Weak / limited. Marketing of specific terpene profiles outpaces the evidence.

What We Don't Know

• Long-term efficacy and safety. Most published trials run 2–15 weeks. Whether pain relief persists, remains stable, or erodes due to tolerance over months or years is unknown. Long-term safety data—particularly on cognition, psychiatric health, and dependence—are limited No data.

• Optimal THC:CBD ratio. Nabiximols uses a 1:1 ratio and shows efficacy for MS pain. Whether 1:1 is optimal for neuropathic pain generally, or whether THC-dominant or CBD-dominant products work better for specific neuropathic subtypes, has not been rigorously tested No data.

• Best route of administration. Inhaled cannabis acts within minutes and wears off within 1–3 hours; oral (edibles, oils) takes 30 minutes to 2 hours and lasts 4–12 hours. Each route has trade-offs in precision of dosing, duration, and side-effect profile. No head-to-head RCTs compare routes for neuropathic pain specifically No data.

• Predictors of response. No reliable clinical feature or biomarker identifies who will respond to cannabis before a trial. Age, sex, pain severity, prior opioid use, and genetic factors have not been systematically studied No data.

• Opioid-sparing effect. Observational data suggest some patients reduce opioid doses when using cannabis. However, RCT evidence is mixed and weaker than headlines suggest Disputed^[11]. Whether combining cannabis and opioids allows safer, lower opioid dosing without sacrificing pain control needs more rigorous study.

Comparison With Standard Treatments

First-line pharmacological treatments for neuropathic pain are defined by international guidelines (NeuPSIG, NICE, American Academy of Neurology) as gabapentin/pregabalin, SNRIs (duloxetine, venlafaxine), and tricyclics (amitriptyline, nortriptyline) Strong evidence^[12][13]. Opioids are increasingly reserved for inadequate response to other agents because of dependence and overdose risks Strong evidence^[12].

Below is a rough comparison of effect size and side-effect profiles. "NNT" (number needed to treat) is the inverse of the difference in pain responders between drug and placebo; lower NNT = more efficient pain relief.

Cannabinoids sit in roughly the same effect-size range as gabapentinoids (NNT 5–11 vs 7–8), with a different side-effect trade-off. Neither is obviously superior; choice depends on individual tolerability. International guidelines generally place cannabinoids as third-line or adjunctive therapy, not because they are clearly inferior, but because the evidence base is smaller, longer-term safety is less established, and first-line agents have decades of clinical use data Strong evidence^[12][13].

Risks, Side Effects, and Contraindications

Common dose-related side effects (occur in 30–50% of trial participants): dizziness, dry mouth, fatigue, cognitive slowing, impaired coordination, euphoria or dysphoria, nausea, somnolence. Roughly 1 in 4 to 1 in 3 trial participants discontinue due to adverse effects Strong evidence^[1][2].

Psychiatric risk. THC can precipitate or worsen psychosis or manic episodes, especially in individuals with personal or strong family history of schizophrenia, bipolar disorder, or other psychotic illness. Cannabis use is contraindicated in these populations Strong evidence.

Cannabis use disorder. Roughly 9–10% of adult cannabis users develop cannabis use disorder (problematic use, dependence); prevalence is higher with daily use and in those starting in adolescence Strong evidence^[14].

Cognitive and driving impairment. Acute THC impairs attention, working memory, and motor coordination for hours after use (inhaled) or up to 8+ hours (oral). Driving or operating machinery is unsafe Strong evidence.

Drug interactions. CBD inhibits liver enzymes CYP2C9, CYP2C19, and CYP3A4. Clinically relevant interactions occur with warfarin (anticoagulant), clobazam (antiepileptic), some statins, and tacrolimus (immunosuppressant). See Cannabis and Polypharmacy Risks.

Cardiovascular. THC increases heart rate and blood pressure acutely. Use with caution in unstable angina, recent myocardial infarction, or significant arrhythmias.

Pregnancy and breastfeeding. Avoid. THC crosses the placenta and is excreted in breast milk; prenatal exposure is associated with impaired neurodevelopment in animal models Strong evidence.

Respiratory (if smoked). Smoking cannabis irritates airways; chronic heavy smoking may increase respiratory symptoms and infection risk, though malignancy risk remains uncertain Strong evidence^[2]. Vaporization or oral forms avoid this.

For a practical guide to starting and titrating cannabis for pain, see Microdosing Cannabis if available.

Summary and Clinical Context

Cannabis and cannabinoids show modest, reproducible pain reduction in some neuropathic pain conditions, with the strongest evidence for MS-related neuropathic pain and HIV-associated sensory neuropathy. Effect sizes are comparable to established first-line agents (gabapentin, pregabalin) but not dramatically superior. Trials are mostly short-term (weeks to a few months); long-term efficacy, optimal dosing, and patient selection remain unclear.

Cannabinoids are reasonable to consider as a third-line or adjunctive option when standard drugs fail, are contraindicated, or cause intolerable side effects. They are not a substitute for established multimodal pain management (physical therapy, psychological support, sleep hygiene) and should be combined with ongoing assessment of efficacy and harms.

Because cannabis remains federally illegal in many jurisdictions and is only partly covered by insurance, access and cost are barriers for many patients. Where available, pharmaceutical formulations like nabiximols may offer more predictable dosing than herbal cannabis or non-regulated products, though they are expensive and not universally available.

Sources

How this page was made

Related

• Cannabis and Cancer Pain — Evidence-based overview of cannabis medicines for cancer pain management.
• Cannabis and Chronic Pain — Evidence summary of cannabis for chronic pain: modest benefit for some, real risks, and ho...
• Cannabis and Lower Back Pain — Evidence review of cannabinoids for chronic low back pain and related conditions.
• Cannabis and Phantom Limb Pain — Evidence, limits, and practical safety for cannabis use in phantom limb pain.
• Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
• THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...